John Oidtman

COO of R&D and SVP, Strategic Business and Development Operations, EMD Serono


John Oidtman is COO of R&D and SVP, Strategic Business & Development Operations (SBDO) at EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany. In this capacity, John is responsible for global project management, R&D governance, R&D informatics and strategic initiatives and global clinical operations. SBDO focuses on operational excellence in the delivery of the R&D portfolio while provisioning efficient, cutting-edge solutions and data insights across the entire R&D value chain to continuously improve our performance in bringing specialty care medicines to patients in need.

John has over 30 years of experience in the global pharmaceutical industry. He has a keen focus on accelerating drug development and strongly believes in fostering a global culture that is reflective of being inclusive and collaborative. He is deeply committed to the cross-functional, global development of his teams and strongly believes in leadership by example. He has initiated a variety of opportunities to lead, introduce and implement new technologies across global organizations; scaling novel innovations to gain a competitive advantage.

John joined EMD Serono in 2017 as Head of Global Clinical Operations.  Prior to EMD, he served within Pfizer’s Global Product Development as Vice President of Global Clinical Trial Execution, with end-to-end oversight of over 400 trials conducted in over 40 countries. From 2011 to 2015, he served as VP of Clinical Trial Support and Compliance with responsibilities that ranged from developing a multi-therapeutic site network and ensuring program feasibility, to overseeing protocol conduct and monitoring site quality across the globe. As VP of Clinical Trial Support and Compliance, John led an enterprise-wide transformation of Pfizer’s in-country Clinical Operations to a fully outsourced model. He began his Pfizer career within the legacy Searle Company in 1997 holding various leadership positions in regulatory affairs at Searle, Pharmacia and Pfizer. Prior to his time at Pfizer, John held positions in toxicology, quality assurance and regulatory affairs at Rhone-Poulenc Rorer.